New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
05:09 EDTPHARMPharming Group announces receipt of $10M milestone payment
Biotech company Pharming Group announced that following the announcement by Pharming and Santarus on November 7 that the pivotal Phase III clinical study of Ruconest, a recombinant human C1 esterase inhibitor, 50 U/kg for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema met its primary endpoint, and in accordance with the terms of the license agreement between Pharming and Santarus, a $10M milestone has now been paid to Pharming. An additional $5M milestone will be payable to Pharming upon FDA acceptance of the Biologics License Application, or BLA, for review. Pharming and Santarus expect to submit the BLA for Ruconest to the FDA in the first half of 2013.
News For PHARM From The Last 14 Days
Check below for free stories on PHARM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
05:24 EDTPHARMSalix, Pharming Group announces FDA approval of Ruconest
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use